The effect of montelukast on wheal reactions in skin prick tests: A double-blind-placebo-controlled randomized trial

Keziban Bulan a, Metin Aydogan b,*, Rengin Siraneci c, Cigdem Yilmaz Aydogmus d

aBakirkoy Maternity and Children’s Education and Research Hospital, Istanbul, Turkey
bKocaeli University, Faculty of Medicine, Department of Pediatric Allergy/Immunology, Kocaeli, Turkey
cDepartment of Infectious Disease, Bakirkoy Maternity and Children’s Education and Research Hospital, Istanbul, Turkey
dDepartments of Allergy & Immunology, Bakirkoy Maternity and Children’s Education and Research Hospital, Istanbul, Turkey

1. Introduction

Skin tests have been used to confirm diseases mediated by IgE such as allergic rhinitis, asthma and anaphylaxis to some allergens such as aeroallergens, foods, insect venoms and certain therapeutic agents [1]. It is known that several drugs may interfere with the reactions in SPTs and make interpretation of these tests more challenging by modulating either flare or wheal. It is known that H1 receptor antagonists suppress the reactions in the SPTs [2,3].

Montelukast is an orally active cysteinyl leukotriene type-1 receptor antagonist of leukotriene D4 with high selectivity [4]. The Allergic Rhinitis and its Impact on Asthma (ARIA) 2010 revision proposed the use of oral leukotriene receptor antagonist in seasonal allergic rhinitis (AR) in both adult and pediatric patients [5]. It is also found to be effective in patients with mild persistent asthma and near-normal pulmonary function [6].

There are limited numbers of randomized, double-blinded, placebo-controlled studies evaluating the potential effects of leukotriene receptor antagonists on cutaneous responses to an allergen in diagnostic procedures with conflicting results [7–11]. All previous studies focusing on the effect of leukotriene receptor antagonists on SPT provided results on the effects of treatments ≤7 days. However, it is imprecise whether it is need to discontinue the treatment with leukotriene receptor antagonists before diagnostic SPT.
In the present study, it was aimed to determine the effect of montelukast treatment (5 mg per day) for 7 and 21 days on wheal reaction in SPT.

2. Methods

2.1. Study group

The study protocol was approved by Institutional Ethics Committee. All subjects gave written informed consent prior to participation.

Children aged 6–15 years with allergic rhinitis and/or mild asthma, who had house dust mite (HDM) sensitivity, were included to the study. Only the patients with skin test positivity to HDM alone were included. Persistent allergic rhinitis was defined according to ARIA guidelines [12]. Asthma was defined as presence or recurrence of at least 2 of 3 symptoms including cough wheezing and shortness of breath within prior 12 months. This clinical definition was solely based on the appearance of recurrent symptoms; thus, it was independent of the hyperresponsiveness level defined in GINA (Global Initiative for Asthma) guidelines [13].

The patients with acute illness or comorbid chronic diseases, those received antihistamines or oral corticosteroid within previous month, those with history of immunotherapy, those with any systemic symptom after skin tests and those with history of adverse reaction to any antihistamines or leukotriene receptor antagonists were excluded.

2.2. Study design

This is a single-center, randomized, double-blinded, placebo-controlled study including two treatment periods with a wash-out interval. The subjects received montelukast (5 mg per day), fexofenadine HCl (60 mg per day) and placebo (lactose) with a double-blinded manner during 7- and 21-days treatment periods with a 14 days wash-out period. Montelukast, fexofenadine and placebo were dispensed as identical tablets. Compliance to treatment regimens were prompted by reminder phone calls and by checking drug containers. Fexofenadine was used as the positive control to assess suppression of wheal and placebo was used as a negative control.

All study medications were prepared by a registered pharmacist at Sanovel Pharmacy and dispensed in double-blinded fashion to all participants.

2.3. Skin test materials

Skin tests were performed between 09:00 and 12:00 AM on the next day after the last dose of study drug or placebo. The disposable, metal prick test lancets (1 mm in length) which were specially designed for SPT were used. *D. farinae* (Allergopharma, Germany) was used as standard allergen extract, while histamine (1 mg/mL; Allergopharma, Germany) as positive and normal saline (Allergopharma, Germany) as negative control.

2.4. Skin test procedure

The skin tests were applied to volar surface of both forearms at a point 5 cm from elbow crease and 3 cm from wrist. There was 3 cm distance between tests. All tests were applied by the same trained researcher, which were then recorded by another researcher blinded to application. Tests were assessed after 20 min. Wheal responses were encircled by using a pen and transferred to a transparent tape. Wheal size was measured as the mean of the longest diameter and midpoint perpendicular diameter. Overall, 7 skin prick tests were performed at following time points: before treatment periods, on the last days of both treatment periods, 24 h after completion of treatment periods, and on the last day of 14-days interval (Fig. 1).

2.5. Statistical analysis

Chi-square test was used for qualitative data. In the analysis, mean of duplicate wheal responses was used. Non-parametric tests were used to analyze mean wheal responses to *D. farinae* in SPT after montelukast, fexofenadine and placebo treatment periods and wash-out period. Wilcoxon rank sum and Mann–Whitney U tests were used for intra-group and inter group analyses, respectively. All tests were two-tailed and p < 0.05 was considered as statistically significant. All statistical analyses were performed by using SPPS for Windows 13.0 (SPSS Inc., Chicago, IL, USA).

3. Results

Overall, 65 HDM allergic children with allergic rhinitis and/or asthma were enrolled to the study. Five children were withdrawn from the study before randomization due to incompliance. The remaining 60 children (23 girls and 37 boys) completed the study and included to primary efficacy analysis. Mean age was 8.3 ± 2.0 years. Patient characteristics according to study groups are summarized in Table 1.

Table 1 Characteristics of the study groups.

<table>
<thead>
<tr>
<th></th>
<th>Montelukast</th>
<th>Fexofenadine</th>
<th>Placebo</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>21</td>
<td>18</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Age (years) (mean ± SD)</td>
<td>8.7 ± 2.1</td>
<td>8.4 ± 2.3</td>
<td>7.8 ± 1.6</td>
<td>0.37</td>
</tr>
<tr>
<td>Sex (girl/boy)</td>
<td>8/13</td>
<td>7/11</td>
<td>8/13</td>
<td>0.98</td>
</tr>
</tbody>
</table>

Tables 2 and 3 present the mean wheal sizes before and after treatment period and at wash-out period and standard deviations for *D. farinae* intradermal challenges in 3 treatment groups. No significant reduction was observed in skin wheal response with montelukast, fexofenadine of placebo use after first treatment period of 7 days (p > 0.05; Table 2).

Fig. 1. The study scheme: Montelukast (5 mg daily) or fexofenadine HCl (60 mg daily) or placebo as a reference drug were given to the volunteers for 7 days and 21 days in a double blind with at least 14 days of wash-out period. Skin prick tests (SPT) were performed pre/posttreatment and first day within wash-out periods, and on the last day of 14-days interval.
The present study was conducted to determine the effect of montelukast (5 mg per day) on wheal response in SPT. It is a randomized, double-blinded, placebo-controlled study using *D. farinae* as allergen extract. Our results demonstrated that montelukast has no effect on the intradermal wheal response at skin after 21 days. As expected, the greatest antigen-induced wheal suppression was recorded in the fexofenadine group.

Leukotrienes are potent pro-inflammatory mediators that induce bronchospasm, mucus secretion, and airway edema [14]. Leukotriene modifiers, either synthesis inhibitors or receptor antagonists, have beneficial effects in terms of improvement in symptoms of asthma and seasonal rhinitis [15]. Leukotriene receptor antagonists (LTRA) prevent the LTD4 binding to its receptor. The clinical efficacy of LTRA has been evaluated in asthma, rhinitis and urticarial in numerous studies [16–18].

It is known that number of drugs including theophylline, β-2 agonists, prochlorperazine, certain sedatives and antihistamines may interfere with wheal reactions in SPT and these drugs should have to be discontinued before skin prick tests to ensure reliable results [19,20]. There are limited numbers of randomized, double-blinded, placebo-controlled studies evaluating the potential effects of leukotriene receptor antagonists on skin responses to an allergen in diagnostic procedures with conflicting results [7–11]. Thus, it is important to establish their effects on the skin test responses. In addition, this causes to interruption of treatments or challenges in the interpretation of tests.

In a study by Juhlin et al., it was reported that a wheal and erythema were observed 15 min after injection, as being most prominent after LTC4 and LTD4 [21]. Leukotriene D4 can induce wheal and flare reactions [22]. Moreover, Atkins et al. showed the time course of leukotriene appearance in inflammatory responses of skin. Authors suggested that leukotrienes could be involved in the delayed- or late-phase response [23].

In a study on 12 atopic individuals, Simons Fe et al. evaluated the effects of montelukast, fexofenadine or combination of these on early and late phase allergic cutaneous reactions. In that study, authors detected a significant reduction with fexofenadine in both early (on the minute 15) and late phase (on the hours 2 and 8) allergic cutaneous reaction in SPT by using histamine and allergen extracts. However, it was seen that montelukast did not affect early and late phase allergic cutaneous reactions in the SPT after 7-days treatment with montelukast by comparing the values obtained during 24-h moniorization after application to those obtained at baseline. They found that there was no significant difference in allergic cutaneous reaction at any time point between combination and fexofenadine alone [7]. Sekerel and Akpinarli reported a suppressive effect with montelukast (5 mg per day) in 30 children with HDM allergy. In that study, the mean reduction in the wheal diameter was significantly greater in the montelukast-treated children at the hour 6 after SPT [8]. On contrary, Kupczyk et al. found that montelukast had no effect on wheal; however, there was a slight, but statistically significant, suppression in flare and itching reaction in SPT [9].

Hill SL and Krouse JH, in their study comparing the effect of 1-week montelukast treatment to loratidine (each 10 mg per day) with placebo on SPT in 23 atopic adults reported a significant suppression from baseline values in loratidine group relative to both placebo and montelukast groups, while no significant difference was found between montelukast and placebo groups [10]. White M et al. reported significant suppression in SPT with but fexofenadine no suppression with montelukast [11]. Similarly, Çuhadaroğlu C et al. reported that zafirlukast did not affect SPT after 5-days treatment and concluded that SPT can be performed in patients on zafirlukast therapy [24].

As mentioned above, no effect of montelukast on skin reactivity was observed in most studies whereas some studies suggested such effect, but these conclusions are based on the results of short-term use of montelukast. To date, the previous studies on the effect of leukotriene receptor antagonists on skin prick tests are based on treatments ≤7 days [7–11]. The effects leukotriene receptor antagonists have not been fully elucidated in long-term use. Our results demonstrated that montelukast has no effect on the intradermal wheal response at skin after 21 days.

In conclusion, our study showed that leukotriene receptor antagonists have no suppressive effect on skin testing. Based on the current results, we conclude that it is not required to discontinue montelukast prior to skin prick test.

### Conflict of interest

The authors declare that have no relevant conflicts of interest.
References